false000117825300011782532025-06-252025-06-25

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

 

 

SCYNEXIS, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36365

56-2181648

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1 Evertrust Plaza

13th Floor

 

Jersey City, New Jersey

 

07302-6548

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 201 884-5485

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

SCYX

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 25, 2025, SCYNEXIS, Inc. held its 2025 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; (b) for, against or abstain for the ratification of the appointment of Deloitte & Touche LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2025; and (c) for, against or abstain for the advisory approval of the executive compensation as disclosed in SCYNEXIS’s proxy statement, filed with the Securities and Exchange Commission on April 30, 2025 (the “Proxy Statement”).

 Proposal 1:

Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS’s 2026 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:

For

Withheld

Broker
Non-Votes

David Angulo, M.D.

13,412,224

1,121,235

12,473,330

Armando Anido

13,309,055

1,224,404

12,473,330

Steven C. Gilman, Ph.D.

13,065,389

1,468,070

12,473,330

Ann F. Hanham, Ph.D.

13,228,680

1,304,779

12,473,330

David Hastings

13,414,768

1,118,691

12,473,330

Guy Macdonald

13,213,263

1,320,196

12,473,330

Philippe Tinmouth

13,371,338

1,162,121

12,473,330

Proposal 2:

The appointment of Deloitte & Touche LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The tabulation of votes on this matter was as follows:

For

Against

Abstain

Broker
Non-Votes

25,543,125

797,439

666,225

Proposal 3:

Advisory approval of the compensation of SCYNEXIS's named executive officers as disclosed in the Proxy Statement, was approved. The tabulation of votes on this matter was as follows:

For

Against

Abstain

Broker
Non-Votes

12,417,323

1,425,389

690,747

12,473,330


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SCYNEXIS, Inc.

 

 

 

 

Date:

July 1, 2025

By:

/s/ David Angulo, M.D.

 

 

Name:

Its:

 David Angulo, M.D.
 Chief Executive Officer